%0 Journal Article
%T 激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌一线治疗的研究进展<br>Research Progress in First-Line Treatment for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
%A 王天琢
%A 迪吉
%J Advances in Clinical Medicine
%P 397-402
%@ 2161-8720
%D 2024
%I Hans Publishing
%R 10.12677/ACM.2024.141057
%X 激素受体阳性(HR+)/人类表皮生长因子受体2阴性(HER2？)乳腺癌是最常见的乳腺癌亚型。大约30%的肿瘤在手术后复发和转移，并且约5%~10%的患者在初次诊断时即被诊断为晚期乳腺癌，对于这类乳腺癌，目前可以选择的治疗方案有许多，包括芳香化酶抑制剂(aromatase inhibitors, AI)、选择性雌激素受体下调剂(fulvestrant)细胞周期蛋白依赖性激酶4/6 (cyclin-dependent kinase 4/6, CDK4/6)抑制剂、磷脂酰肌醇-3-激酶(phosphatidylinositiol-3-kinases, PI3K)、丝氨酸/苏氨酸蛋白激酶(proteinserine-threonine kinase, AKT)抑制剂、雷帕霉素靶蛋白(mammalian target of rapamycin, mTOR)抑制剂、组蛋白脱乙酰酶(histone deacetylase, HDAC)抑制剂等。本文以内脏危象为分层就HR+/HER2？型乳腺癌一线治疗方面的研究进行综述，以期为乳腺癌患者的精准治疗提供理论基础。<br />
Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2？) breast cancer is the most common subtype of breast cancer. Approximately 30% of tumors experi-ence recurrence and metastasis after surgery, and about 5%~10% of patients are diagnosed with advanced breast cancer at the initial diagnosis. For this type of breast cancer, there are various treatment options available, including aromatase inhibitors (AI), selective estrogen receptor de-graders (fulvestrant), cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, phosphatidylinositiol- 3-kinases (PI3K), proteinserine-threonine kinase (AKT) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, histone deacetylase (HDAC) inhibitors, and others. This article reviews research on first-line treatment for HR+/HER2？ breast cancer, stratified by visceral crisis, aiming to provide a theoretical basis for precision treatment of breast cancer patients.
%K 乳腺癌，晚期一线治疗，内分泌治疗，靶向治疗<br>Breast Cancer
%K Advanced First-Line Treatment
%K Endocrine Therapy
%K Targeted Therapy
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=78993